A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.

NCT00721266 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
102
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Hoffmann-La Roche